



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Summary of Main Points from the Meeting held on Monday 13<sup>th</sup> November 2017**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the 9<sup>th</sup> October 2017 Medicines Group meeting were approved and will be circulated.

**3. Matters Arising**

The Group noted the matters arising from the previous meeting.

**4. Business to be transacted by the Medicines Group**

**4.1 Formulary Applications**

***Full Applications***

Nil

***Ex-Panel Requests***

• **Raltegravir 600mg Tablets (Isentress<sup>®</sup>)**

Licensed dose: 1200mg tablets OD

Currently using 400mg tablets at a dose of 800mg OD off-licensed. Licensed dose: 400mg BD

Funding: NHSE agreed

Raltegravir is the 1<sup>st</sup> line ARV drug in London guidance.

**Decision: Approved**

• **Raltegravir 100mg Granules for oral suspension (Isentress<sup>®</sup>)**

NHSE agreed for use in neonates to prevent HIV transmission as PEP where mother has HIV.

**Decision: Approved**

• **Budesonide 9mg (Prolonged Release) Tablets**

Budesonide 9mg (Prolonged Release) Tablets (Cortiment<sup>®</sup>) are the only budesonide formulation licensed for the treatment of Ulcerative Colitis.

Current formulary choice Budesonide 3mg MR capsules (Budenofalk<sup>®</sup>) are only licensed for Crohn's Disease.

Entocort<sup>®</sup> 3mg CR Capsules is also currently on the formulary for use in Paediatrics for Crohn's Disease who have agreed to switch over to prescribing budenofalk<sup>®</sup> instead.

**Decision: Approved**

**4.2 Trust Medicines Policy**

• **TMP: Section 28 - CD Governance Arrangements**

Updated to include new NHS England Occurrence Report template

Removal of all references to CNWL

**Decision: Approved**

**4.3 Medicines Optimisation**

• **Rituximab IV Administration chart**

Updated chart reviewed following comments received at the October meeting:

Further updated following comments received and discussions with prof Callan.

**Decision: Approved**

• **Patient Information Leaflet**

Patient Information Leaflet relating to the New Medicine Service

**Decision: Approved**

• **Response from CWFT re. low priority medicine items**

Response from CWFT regarding low priority medicines item



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Decision: Noted**

- **Daily Tadalafil - Position Statement**

Position statement from NCL on the prescribing of Daily Tadalafil

**Decision: Noted**

- **Lidocaine 5% plaster - Position statement**

Position statement from NCL on the prescribing of Lidocaine 5% Plasters

**Decision: Noted**

- **CCP Monthly Report - October 2017**

Monthly CCP Report for October 2017

**Decision: Noted**

#### **4.4 NICE TA Guidance**

**NICE TA Guidance - September 2017**

**6 Appraisals were published in October 2017**

**TA477 - Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee**

**This is a procedure and not relating to any medicines therefore no impact on the formulary**

**TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma**

**Currently included on formulary**

**TA479 - Reslizumab for treating severe eosinophilic asthma**

**Currently not included on formulary. For Specialist Respiratory Centres only - Not applicable to C&W**

**TA480 - Tofacitinib for moderate to severe rheumatoid arthritis**

**Currently not included on formulary - Will add to formulary following receipt of complete from the Rheumatology Team**

**TA481 - Immunosuppressive therapy for kidney transplant in adults**

**Currently not included on formulary - Not applicable to C&W**

**TA482 - Immunosuppressive therapy for kidney transplant in children and young people**

**Currently not included on formulary - Not applicable to C&W**

#### **4.5 IVIG Update**

- **IVIG requests**

**October 2017**

**CWH Site**

There were 20 IVIG issues in October 2017, with 6 new requests

**WMUH Site**

There were 23 IVIG issues in October 2017, with 5 new requests

**Decision: Approved**

#### **4.6 Items for noting**

- **Quarterly Q2 2017/18 Controlled Drug Summary Report**

Quarterly Controlled Drug Summary Report for Q2 2017/18

**Decision: Noted**



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

- **Quarterly Q2 2017/18 Controlled Drugs Accountable Officer**

Quarterly Controlled Drugs Accountable Officer for Q2 2017/18

**Decision: Noted**

- **MHRA Drug Safety Update - October 2017**

MHRA update for October 2017

**Decision: Noted**

**4.7 Meeting minutes for noting**

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - August 2017**

Minutes for HIV/GUM Directorate - Medicines Sub-Group Meeting - August 2017

**Decision: Noted**

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - September 2017**

Minutes for HIV/GUM Directorate - Medicines Sub-Group Meeting - September 2017

**Decision: Noted**

**4.8 Additional papers to go to Trust patient Safety Group**

Quarterly Q2 2017/18 Controlled Drug Summary Report

Quarterly Q2 2017/18 Controlled Drugs Accountable Officer Report

**5. Any other business**

Nil

**6. Date of next meeting**

**Date: Monday 11<sup>th</sup> December 2017**

**Time: 8am-9am**

**Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)**

**Closing date: 17<sup>th</sup> November 2017**